Gelesis is a commercial stage biotherapeutics company built for consumer engagement. We are focused on advancing first-in-class superabsorbent hydrogel therapeutics for chronic gastrointestinal, or GI, diseases including excess weight, type 2 diabetes, non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (“NAFLD/NASH”), functional constipation (“FC”), and inflammatory bowel disease. Our biomimetic superabsorbent hydrogels are inspired by the composition and mechanical properties (e.g. firmness) of raw vegetables. They are conveniently administered in capsules taken with water to create a much larger volume of small, non-aggregating hydrogel pieces that become an integrated part of the meals, and act locally in the digestive system.
Company profile
Ticker
GLSHQ, GLSWQ
Exchange
Website
CEO
Yishai Zohar
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CAPSTAR SPECIAL PURPOSE ACQUISITION CORP.
SEC CIK
Corporate docs
Subsidiaries
Gelesis, Inc. • Gelesis S.r.l. ...
IRS number
844730610
GLSHQ stock data
Latest filings (excl ownership)
8-K
Bankruptcy or Receivership
30 Oct 23
CT ORDER
Confidential treatment order
19 Oct 23
8-K
Termination of a Material Definitive Agreement
16 Oct 23
SC 13E3/A
Going private transaction (amended)
29 Sep 23
PRER14A
Preliminary revised proxy
29 Sep 23
8-K
Entry into a Material Definitive Agreement
20 Sep 23
SC 13E3/A
Going private transaction (amended)
7 Sep 23
PRER14A
Preliminary revised proxy
7 Sep 23
8-K
Regulation FD Disclosure
6 Sep 23
8-K
Departure of Directors or Certain Officers
21 Aug 23
Latest ownership filings
SC 13D/A
PureTech Health LLC
16 Oct 23
SC 13D/A
PureTech Health LLC
21 Sep 23
4
Change in insider ownership
21 Sep 23
SC 13D/A
PureTech Health LLC
29 Jun 23
4
Change in insider ownership
14 Jun 23
SC 13D/A
PureTech Health LLC
13 Jun 23
4
Change in insider ownership
31 May 23
SC 13D/A
PureTech Health LLC
30 May 23
4
Change in insider ownership
3 May 23
SC 13D/A
PureTech Health LLC
2 May 23
Financial summary
Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 7.91 mm | 7.91 mm | 7.91 mm | 7.91 mm | 7.91 mm | 7.91 mm |
Cash burn (monthly) | (no burn) | 1.45 mm | 3.33 mm | 5.53 mm | (no burn) | 3.84 mm |
Cash used (since last report) | n/a | 14.82 mm | 34.00 mm | 56.41 mm | n/a | 39.14 mm |
Cash remaining | n/a | -6.91 mm | -26.09 mm | -48.50 mm | n/a | -31.23 mm |
Runway (months of cash) | n/a | -4.8 | -7.8 | -8.8 | n/a | -8.1 |
Institutional ownership, Q2 2023
46.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 6 |
Opened positions | 0 |
Closed positions | 37 |
Increased positions | 0 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 5.17 mm |
Total shares | 33.85 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
SSD2 | 13.41 mm | $4.10 mm |
HPSO SPV | 12.18 mm | $0.00 |
CMS Medical Venture Investment | 4.50 mm | $0.00 |
Pacific Investment Management | 3.76 mm | $1.05 mm |
Russell Investments | 378.00 | $14.00 k |
BCS Barclays | 52.00 | $0.00 |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 Sep 23 | PureTech Health | Convertible Note Common Stock | Buy | Acquire P | Yes | No | 1500000 | - | 1.50 mm | - |
12 Jun 23 | PureTech Health | Convertible Note Common Stock | Buy | Acquire P | Yes | No | 3000000 | - | 3.00 mm | - |
26 May 23 | PureTech Health | Warrants Common Stock | Buy | Acquire P | Yes | No | 0.0142 | 43,133,803 | 612.50 k | 43,133,803 |
26 May 23 | PureTech Health | Convertible Note Common Stock | Buy | Acquire P | Yes | No | 350000 | - | 350.00 k | - |
1 May 23 | PureTech Health | Warrants Common Stock | Buy | Acquire P | Yes | No | 0.0182 | 192,307,692 | 3.50 mm | 192,307,692 |
1 May 23 | PureTech Health | Warrants Common Stock | Buy | Acquire P | Yes | No | 0.2744 | 23,688,047 | 6.50 mm | 23,688,047 |
1 May 23 | PureTech Health | Convertible Note Common Stock | Buy | Acquire P | Yes | No | 1 | 2,000,000 | 2.00 mm | 2,000,000 |
1 May 23 | PureTech Health | Convertible Note Common Stock | Buy | Acquire P | Yes | No | 1 | 5,000,000 | 5.00 mm | 5,000,000 |
21 Nov 22 | Raju S Kucherlapati | Common Stock | Buy | Acquire P | No | No | 0.45 | 92,000 | 41.40 k | 190,264 |
18 Nov 22 | Raju S Kucherlapati | Common Stock | Buy | Acquire P | No | No | 0.39 | 8,000 | 3.12 k | 98,264 |